Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Clinical trial NCT00423332 · COMPLETED

Trial details

NCT number: NCT00423332
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Renal Cell Carcinoma

Start date: 2007-01-01
Primary completion: 2008-03-01
Enrollment: 105

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.